206 related articles for article (PubMed ID: 8794347)
1. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.
Zhou H; O'Neal W; Morral N; Beaudet AL
J Virol; 1996 Oct; 70(10):7030-8. PubMed ID: 8794347
[TBL] [Abstract][Full Text] [Related]
2. A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector.
Zhou H; Zhao T; Pastore L; Nageh M; Zheng W; Rao XM; Beaudet AL
Mol Ther; 2001 Apr; 3(4):613-22. PubMed ID: 11319924
[TBL] [Abstract][Full Text] [Related]
3. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.
Gorziglia MI; Lapcevich C; Roy S; Kang Q; Kadan M; Wu V; Pechan P; Kaleko M
J Virol; 1999 Jul; 73(7):6048-55. PubMed ID: 10364357
[TBL] [Abstract][Full Text] [Related]
4. A new vector system with inducible E2a cell line for production of higher titer and safer adenoviral vectors.
Zhou H; Beaudet AL
Virology; 2000 Sep; 275(2):348-57. PubMed ID: 10998335
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.
Lusky M; Christ M; Rittner K; Dieterle A; Dreyer D; Mourot B; Schultz H; Stoeckel F; Pavirani A; Mehtali M
J Virol; 1998 Mar; 72(3):2022-32. PubMed ID: 9499056
[TBL] [Abstract][Full Text] [Related]
6. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.
Morral N; O'Neal W; Zhou H; Langston C; Beaudet A
Hum Gene Ther; 1997 Jul; 8(10):1275-86. PubMed ID: 9215744
[TBL] [Abstract][Full Text] [Related]
7. An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.
Catalucci D; Sporeno E; Cirillo A; Ciliberto G; Nicosia A; Colloca S
J Virol; 2005 May; 79(10):6400-9. PubMed ID: 15858023
[TBL] [Abstract][Full Text] [Related]
8. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
9. Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses.
Raper SE; Haskal ZJ; Ye X; Pugh C; Furth EE; Gao GP; Wilson JM
Hum Gene Ther; 1998 Mar; 9(5):671-9. PubMed ID: 9551615
[TBL] [Abstract][Full Text] [Related]
10. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted.
Amalfitano A; Hauser MA; Hu H; Serra D; Begy CR; Chamberlain JS
J Virol; 1998 Feb; 72(2):926-33. PubMed ID: 9444984
[TBL] [Abstract][Full Text] [Related]
11. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4.
Brough DE; Lizonova A; Hsu C; Kulesa VA; Kovesdi I
J Virol; 1996 Sep; 70(9):6497-501. PubMed ID: 8709289
[TBL] [Abstract][Full Text] [Related]
12. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
Osada T; Yang XY; Hartman ZC; Glass O; Hodges BL; Niedzwiecki D; Morse MA; Lyerly HK; Amalfitano A; Clay TM
Cancer Gene Ther; 2009 Sep; 16(9):673-82. PubMed ID: 19229288
[TBL] [Abstract][Full Text] [Related]
13. Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro.
Rittner K; Schultz H; Pavirani A; Mehtali M
J Virol; 1997 Apr; 71(4):3307-11. PubMed ID: 9060700
[TBL] [Abstract][Full Text] [Related]
14. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
15. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.
Engelhardt JF; Ye X; Doranz B; Wilson JM
Proc Natl Acad Sci U S A; 1994 Jun; 91(13):6196-200. PubMed ID: 8016137
[TBL] [Abstract][Full Text] [Related]
16. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants.
Krougliak V; Graham FL
Hum Gene Ther; 1995 Dec; 6(12):1575-86. PubMed ID: 8664382
[TBL] [Abstract][Full Text] [Related]
17. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy.
Gorziglia MI; Kadan MJ; Yei S; Lim J; Lee GM; Luthra R; Trapnell BC
J Virol; 1996 Jun; 70(6):4173-8. PubMed ID: 8648763
[TBL] [Abstract][Full Text] [Related]
18. Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs.
Fang B; Wang H; Gordon G; Bellinger DA; Read MS; Brinkhous KM; Woo SL; Eisensmith RC
Gene Ther; 1996 Mar; 3(3):217-22. PubMed ID: 8646552
[TBL] [Abstract][Full Text] [Related]
19. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector.
Wang Q; Greenburg G; Bunch D; Farson D; Finer MH
Gene Ther; 1997 May; 4(5):393-400. PubMed ID: 9274715
[TBL] [Abstract][Full Text] [Related]
20. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study.
Goldman MJ; Litzky LA; Engelhardt JF; Wilson JM
Hum Gene Ther; 1995 Jul; 6(7):839-51. PubMed ID: 7578403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
